Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage biopharmaceutical company, Thursday announced that it will implement a 1-for-15 reverse stock split effective August 15.
Trading on a split-adjusted basis will begin August 18, 2025, under a new CUSIP number.
The move aims to restore compliance with Nasdaq's $1.00 minimum bid price requirement. Shareholders approved the split at a July 8, 2025 meeting, authorizing the board to select the ratio.
The adjustment will reduce outstanding shares from about 7.6 million to approximately 509,000, with proportional changes to outstanding options, warrants, and reserved shares.
Ownership percentages will remain unchanged, though fractional shares will be cashed out based on the August 15 closing price.
SLRX is currently trading at $0.46, down $0.02 or 4.28 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.